Veracyte reported Q1 revenue of $139.1 million, up 21% year over year, and raised full-year revenue guidance after Decipher prostate and Afirma thyroid product volumes grew faster than expected. The company’s testing revenue rose 26% to $135.1 million, with Decipher growing 30% to $86.5 million and Afirma increasing 21% to $46.4 million. Veracyte linked momentum to expanding clinical evidence and said it is approaching an inflection ahead of upcoming launches including Prosigna LDT and TrueMRD. Management also emphasized that guidance increases are paired with profitability targets, despite higher Q1 R&D expenses, which rose 53% to $27.1 million. Veracyte reported Q1 net income of $28.7 million and adjusted EPS of $0.52. For 2026, Veracyte lifted revenue guidance to $582 million–$592 million and testing revenue guidance to $570 million–$580 million, citing market expansion opportunities across breast, bladder and other cancers alongside continued prostate and thyroid growth.